Fusion Pharmaceuticals Inc. (NASDAQ:FUSN – Get Rating) – Wedbush decreased their Q2 2022 earnings per share (EPS) estimates for shares of Fusion Pharmaceuticals in a research report issued to clients and investors on Tuesday, May 10th. Wedbush analyst D. Nierengarten now anticipates that the company will earn ($0.53) per share for the quarter, down from their prior forecast of ($0.48). Wedbush has a “Outperform” rating and a $19.00 price objective on the stock. Wedbush also issued estimates for Fusion Pharmaceuticals’ Q3 2022 earnings at ($0.59) EPS, Q4 2022 earnings at ($0.43) EPS, FY2022 earnings at ($1.98) EPS, FY2023 earnings at ($1.68) EPS, FY2024 earnings at ($2.52) EPS and FY2025 earnings at ($2.60) EPS.
Fusion Pharmaceuticals (NASDAQ:FUSN – Get Rating) last issued its quarterly earnings data on Thursday, March 17th. The company reported ($0.40) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.47) by $0.07. Fusion Pharmaceuticals had a negative return on equity of 33.75% and a negative net margin of 4,119.85%. The firm had revenue of $0.59 million during the quarter.
Shares of FUSN opened at $3.82 on Friday. Fusion Pharmaceuticals has a 52 week low of $3.71 and a 52 week high of $10.40. The stock’s 50-day moving average price is $6.53 and its 200-day moving average price is $6.49.
In related news, CEO John Valliant sold 4,100 shares of the firm’s stock in a transaction that occurred on Tuesday, February 22nd. The shares were sold at an average price of $7.85, for a total value of $32,185.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders sold 70,834 shares of company stock worth $517,192 in the last 90 days. 6.12% of the stock is owned by company insiders.
Institutional investors have recently modified their holdings of the stock. Goldman Sachs Group Inc. grew its holdings in shares of Fusion Pharmaceuticals by 10.6% in the 3rd quarter. Goldman Sachs Group Inc. now owns 20,149 shares of the company’s stock valued at $160,000 after acquiring an additional 1,928 shares in the last quarter. Geode Capital Management LLC grew its stake in shares of Fusion Pharmaceuticals by 8.9% in the third quarter. Geode Capital Management LLC now owns 25,136 shares of the company’s stock worth $199,000 after purchasing an additional 2,047 shares during the last quarter. Millennium Management LLC bought a new stake in Fusion Pharmaceuticals during the third quarter valued at $213,000. Sectoral Asset Management Inc acquired a new position in shares of Fusion Pharmaceuticals during the third quarter valued at about $303,000. Finally, AlphaCentric Advisors LLC acquired a new stake in shares of Fusion Pharmaceuticals in the 4th quarter worth about $417,000. 64.25% of the stock is currently owned by institutional investors and hedge funds.
Fusion Pharmaceuticals Company Profile (Get Rating)
Fusion Pharmaceuticals Inc, a clinical-stage oncology company, focuses on developing radiopharmaceuticals as precision medicines. The company has developed Targeted Alpha Therapies platform together with its proprietary Fast-Clear linker technology to enable us to connect alpha particle emitting isotopes to various targeting molecules in order to selectively deliver the alpha particle payloads to tumors.
- Get a free copy of the StockNews.com research report on Fusion Pharmaceuticals (FUSN)
- Is Electronic Arts (NASDAQ: EA) Suddenly A Safe Haven?
- Beyond Meat Stock Value is Improving
- The Travel Sector Is Getting Upgraded
- Carvana Insiders Buy Shares But Maybe You Shouldn’t
- Dutch Bros Gets Scalded By Inflation
Receive News & Ratings for Fusion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fusion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.